Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2 Open-Label, Dose Escalation & Expansion Study of Orally Administered VRx-3996 & Valganciclovir in Subjects With Epstein-Barr Virus-Associated Lymphoid Malignancies

Next Previous
Trial Profile

A Phase 1b/2 Open-Label, Dose Escalation & Expansion Study of Orally Administered VRx-3996 & Valganciclovir in Subjects With Epstein-Barr Virus-Associated Lymphoid Malignancies

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 01 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nanatinostat/valganciclovir combination therapy (Primary) ; Valganciclovir (Primary)
  • Indications B-cell lymphoma; Cutaneous T-cell lymphoma; Diffuse large B cell lymphoma; Extranodal NK-T-cell lymphoma; Hodgkin's disease; Lymphoproliferative disorders; Peripheral T-cell lymphoma; Post-transplant lymphoproliferative disorder; T-cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Viracta Therapeutics

    • Most Recent Events

    • 04 Oct 2023 According to a Viracta Therapeutics media release, company's plans to highlight new preliminary clinical data from this study during an R&D Day.
    • 08 Aug 2023 According to a Viracta Therapeutics media release, data published from this trial supports the recently announced expansion of EBV-positive peripheral T-cell lymphoma cohort, representing an exciting time for clinical trial program and the company look forward to providing more updates on its progress in the future.
    • 08 Aug 2023 According to a Viracta Therapeutics media release, results from this trial were published in the Blood Advances.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top